332 related articles for article (PubMed ID: 17284533)
1. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.
Venturini L; Battmer K; Castoldi M; Schultheis B; Hochhaus A; Muckenthaler MU; Ganser A; Eder M; Scherr M
Blood; 2007 May; 109(10):4399-405. PubMed ID: 17284533
[TBL] [Abstract][Full Text] [Related]
2. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
4. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.
Agirre X; Jiménez-Velasco A; San José-Enériz E; Garate L; Bandrés E; Cordeu L; Aparicio O; Saez B; Navarro G; Vilas-Zornoza A; Pérez-Roger I; García-Foncillas J; Torres A; Heiniger A; Calasanz MJ; Fortes P; Román-Gómez J; Prósper F
Mol Cancer Res; 2008 Dec; 6(12):1830-40. PubMed ID: 19074828
[TBL] [Abstract][Full Text] [Related]
6. The malignancy suppression role of miR-23a by targeting the BCR/ABL oncogene in chromic myeloid leukemia.
Xishan Z; Xianjun L; Ziying L; Guangxin C; Gang L
Cancer Gene Ther; 2014 Sep; 21(9):397-404. PubMed ID: 25213664
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
9. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
10. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
11. MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27.
Wang L; Wang Y; Lin J
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8789-8796. PubMed ID: 30575920
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
[TBL] [Abstract][Full Text] [Related]
13. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
14. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
15. Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Liu N; Li P; Zang S; Liu Q; Ma D; Sun X; Ji C
PLoS One; 2015; 10(2):e0116880. PubMed ID: 25647305
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
18. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
[TBL] [Abstract][Full Text] [Related]
20. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
Flamant S; Ritchie W; Guilhot J; Holst J; Bonnet ML; Chomel JC; Guilhot F; Turhan AG; Rasko JE
Haematologica; 2010 Aug; 95(8):1325-33. PubMed ID: 20460641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
